View in EDS

Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.

Saved in:
Bibliographic Details
Title: Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Authors: Nikolaou A; Modelling and Simulation, Evidera, London, UK., Ambavane A; Modelling and Simulation, Evidera, Waltham, MA, USA., Shah A; Modelling and Simulation, Evidera, Waltham, MA, USA., Ma W; Modelling and Simulation, Evidera, Waltham, MA, USA., Tosh J; Modelling and Simulation, Evidera, London, UK., Kapetanakis V; Modelling and Simulation, Evidera, London, UK., Willson J; GlaxoSmithKline, Upper Providence, PA, USA., Wang F; GlaxoSmithKline, Upper Providence, PA, USA., Hogea C; GlaxoSmithKline, Philadelphia, PA, USA., Gorsh B; GlaxoSmithKline, Philadelphia, PA, USA., Gutierrez B; GlaxoSmithKline, Philadelphia, PA, USA., Sapra S; GlaxoSmithKline, Philadelphia, PA, USA., Suvannasankha A; Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA., Samyshkin Y; GlaxoSmithKline, Brentford, Middlesex, UK.
Source: Expert review of hematology [Expert Rev Hematol] 2021 Dec; Vol. 14 (12), pp. 1137-1145. Date of Electronic Publication: 2021 Sep 20.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485942 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1747-4094 (Electronic) Linking ISSN: 17474094 NLM ISO Abbreviation: Expert Rev Hematol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34465265
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Nikolaou+A%22">Nikolaou A</searchLink>; Modelling and Simulation, Evidera, London, UK.<br /><searchLink fieldCode="AU" term="%22Ambavane+A%22">Ambavane A</searchLink>; Modelling and Simulation, Evidera, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Shah+A%22">Shah A</searchLink>; Modelling and Simulation, Evidera, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Ma+W%22">Ma W</searchLink>; Modelling and Simulation, Evidera, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Tosh+J%22">Tosh J</searchLink>; Modelling and Simulation, Evidera, London, UK.<br /><searchLink fieldCode="AU" term="%22Kapetanakis+V%22">Kapetanakis V</searchLink>; Modelling and Simulation, Evidera, London, UK.<br /><searchLink fieldCode="AU" term="%22Willson+J%22">Willson J</searchLink>; GlaxoSmithKline, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Wang+F%22">Wang F</searchLink>; GlaxoSmithKline, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Hogea+C%22">Hogea C</searchLink>; GlaxoSmithKline, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Gorsh+B%22">Gorsh B</searchLink>; GlaxoSmithKline, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Gutierrez+B%22">Gutierrez B</searchLink>; GlaxoSmithKline, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Sapra+S%22">Sapra S</searchLink>; GlaxoSmithKline, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Suvannasankha+A%22">Suvannasankha A</searchLink>; Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USA.<br /><searchLink fieldCode="AU" term="%22Samyshkin+Y%22">Samyshkin Y</searchLink>; GlaxoSmithKline, Brentford, Middlesex, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101485942%22">Expert review of hematology</searchLink> [Expert Rev Hematol] 2021 Dec; Vol. 14 (12), pp. 1137-1145. <i>Date of Electronic Publication: </i>2021 Sep 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101485942 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1747-4094 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217474094%22">17474094 </searchLink><i>NLM ISO Abbreviation: </i>Expert Rev Hematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34465265
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/17474086.2021.1970522
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1137
    Titles:
      – TitleFull: Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Nikolaou A
      – PersonEntity:
          Name:
            NameFull: Ambavane A
      – PersonEntity:
          Name:
            NameFull: Shah A
      – PersonEntity:
          Name:
            NameFull: Ma W
      – PersonEntity:
          Name:
            NameFull: Tosh J
      – PersonEntity:
          Name:
            NameFull: Kapetanakis V
      – PersonEntity:
          Name:
            NameFull: Willson J
      – PersonEntity:
          Name:
            NameFull: Wang F
      – PersonEntity:
          Name:
            NameFull: Hogea C
      – PersonEntity:
          Name:
            NameFull: Gorsh B
      – PersonEntity:
          Name:
            NameFull: Gutierrez B
      – PersonEntity:
          Name:
            NameFull: Sapra S
      – PersonEntity:
          Name:
            NameFull: Suvannasankha A
      – PersonEntity:
          Name:
            NameFull: Samyshkin Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2021 Dec
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1747-4094
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: Expert review of hematology
              Type: main
ResultId 1